行情

FCSC

FCSC

Fibrocel Science
NASDAQ

实时行情|Nasdaq Last Sale

2.990
0.000
0.00%
已收盘, 16:00 12/06 EST
开盘
2.990
昨收
2.990
最高
3.000
最低
2.990
成交量
2.34万
成交额
--
52周最高
3.280
52周最低
1.450
市值
2,917.74万
市盈率(TTM)
-8.0247
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FCSC 新闻

  • 美农场破产量飙升24%创6年新高 农业危机“在路上”?
  • 第一财经.3天前
  • 资金流向复盘 | 南下资金今日净流入港股超28亿港元
  • 华盛通.3天前
  • 瑞银:欧央行利率会议中性看待欧元 明年有望徐徐上涨
  • 新浪财经综合.3天前
  • 巴西“黑五”电商收入32亿雷亚尔 285万人“剁手”
  • 中国新闻网.3天前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

FCSC 简况

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
展开

Webull提供Fibrocell Science Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。